Title : Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).

Pub. Date : 2020 Dec

PMID : 33070053






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Since the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, may attenuate and/or prevent BRCA1 expression, the addition of olaparib to gefitinib could improve outcome in EGFR-mutant advanced NSCLC. olaparib epidermal growth factor receptor Homo sapiens